SOLV Stock Recent News

ST. PAUL, Minn. , Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) (the "Company" or "Solventum") today announced the pricing of the previously announced secondary offering (the "Offering") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the "Selling Shareholder").

ST. PAUL, Minn. , Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV, "Company" or "Solventum") today announced the launch of a secondary offering (the "Offering") of 8,800,000 shares of its common stock, par value $0.01 per share, by 3M Company (the "Selling Shareholder").

SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.

Solventum Corporation (NYSE:SOLV ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan C. Hanson - CEO & Director Wayde D.

Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Solventum (SOLV) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.56 per share a year ago.

Solventum (SOLV) Fiscal Q2 EPS Jumps 8%

Medical device maker Solventum raised full-year adjusted profit forecast on Thursday, driven by strong sales of its wound care and surgical sterilization products alongside lower expenses.

Reported sales increased 3.9%; organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 ST. PAUL, Minn.

SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.